Skip to content

Oruka Therapeutics, Inc. ORKA Non Cash Lease Expense

Non Cash Lease Expense at other companies

Rigetti Computing, Inc. logo
Rigetti Computing, Inc.RGTI
$419K+9.1%
Dave, Inc. logo
Dave, Inc.DAVE
$0+100%
CG Oncology logo
CG OncologyCGON
$13K+193%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$116K+54.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$439K-22.8%
Urban Outfitters logo
Urban OutfittersURBN
$53.31M+1.0%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept orka:NonCashLeaseExpense.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s non cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s non cash lease expense?
Oruka Therapeutics, Inc. (ORKA) reported non cash lease expense of $143K in Q1 2026.
What does non cash lease expense mean?
This represents the portion of lease expenses that does not involve an immediate cash outflow, typically related to the amortization of right-of-use assets. It is a non-cash adjustment used to reconcile net income with operating cash flows under current lease accounting standards. Investors use this to isolate the actual cash impact of lease obligations from non-cash accounting charges.